SCHEMBL12640342

SCHEMBL12640342

Cc1cc(Br)cnc1NCc1ccc(C(F)(F)F)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.48
CYP2C19 P33261 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAPT P10636 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP3A4 P08684 2/20 0.44
P2RX3 P56373 2/20 0.43
P2RX2 Q9UBL9 2/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
KCNQ4 P56696 1/20 0.41
KCNQ5 Q9NR82 1/20 0.41
CSF1R P07333 4/20 0.41
BCDIN3D Q7Z5W3 1/20 0.40
KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599938 0.86 CYP2C9 (0.54) CYP2C9CYP2C19ALDH1A1CYP1A2CYP2D6
SCHEMBL2599931 0.84 CYP3A4 (0.48) CYP2C9CYP2C19ALDH1A1CYP1A2CYP2D6
SCHEMBL12640377 0.82 CYP2C9 (0.47) CYP2C9CYP2C19CYP3A4P2RX3P2RX2
SCHEMBL12640338 0.80 KDM4E (0.53) CYP2C9CYP2C19ALDH1A1CYP1A2CYP2D6
SCHEMBL2599923 0.78 CYP3A4 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2CYP2D6
SCHEMBL22663421 0.77 CSF1R (0.52) CYP2C9CYP2C19CYP3A4CNR1CNR2
SCHEMBL2599920 0.76 NPC1 (0.52) CYP2C19ALDH1A1MAPTCYP3A4P2RX3
SCHEMBL1883690 0.73 CYP2C9 (0.84) CYP2C9CYP2C19CYP2D6CYP3A4CSF1R
SCHEMBL12640348 0.72 CD38 (0.43) CYP2C19MAPTCYP3A4PRKCQ
SCHEMBL12640336 0.72 ALDH1A1 (0.42) CYP2C9CYP2C19ALDH1A1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 WO disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP2C9 3884/4885CYP2C19 4018/4885ALDH1A1 2981/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP2C9 3884/4885CYP2C19 4018/4885ALDH1A1 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.